Introduction
Lymphomas are malignant lymphoproliferative disorders that can manifest in lymph nodes or extra-nodal sites. They are broadly categorized as either Hodgkin's lymphoma, arising from pre-B-cells, or non-Hodgkin's lymphoma (NHL), arising from the monoclonal development of malignant B- and T-cells ( 1 , 2 ). Primary lymphoma of bone (PLB), first described in 1928, is a rare form of extra-nodal NHL, accounting for just 1% of all malignant lymphomas and 4–5% of primary malignant bone tumors ( 2 , 3 ). Approximately 80% of PLB cases are the diffuse large B-cell lymphoma (DLBCL) subtype, which responds well to immunochemotherapy regimens such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) ( 4 ).
While PLB is a curable disease, its diagnosis can be complex ( 5 ). Its histopathological appearance, characterized by sheets of small round cells, can mimic other primary bone tumors, including Ewing's sarcoma, small cell osteosarcoma and neuroblastoma ( 6 ). Immunohistochemistry is therefore an indispensable tool for differentiating these entities and ensuring an accurate diagnosis. The present case is unique, as it illustrates PLB's diagnostic challenges and the management of a significant, long-term complication following standard therapy. While pathological fractures are known to occur in PLB, this report details a novel surgical reconstruction for a non-healing fracture post-treatment, employing a reverse shoulder megaprosthesis with a cryo-treated autograft to restore function. This combination is rarely, if ever, used to treat this specific and complex diagnosis.
Case report
A 42-year-old male with no significant past medical history presented to the Vietnam National Cancer Hospital (Hanoi, Vietnam) in November 2022 with a 5-month history of persistent pain in the proximal left humerus. The patient did not report any B symptoms, such as fever, night sweats or weight loss. Initial X-rays revealed an aggressive bone lesion in the proximal humerus with mixed lytic and sclerotic areas, a moth-eaten pattern and a wide zone of transition. The lesion exhibited cortical destruction and extended from the humeral head to the middle third of the humeral shaft, with suspected soft-tissue involvement. An open biopsy was performed and pathology results confirmed NHL.
The patient was diagnosed with Stage IV NHL of the left humerus (Ann Arbor staging system) ( 7 ). The patient was treated with 6 cycles of R-CHOP chemotherapy (Rituximab 375 mg/m 2 on day 1, Cyclophosphamide 750 mg/m 2 on day 1, Doxorubicin 50 mg/m 2 on day 1, Vincristine 1.4 mg/m 2 on day 1, Prednisolone 100 mg on day 1–5) from January to August 2023, followed by 36 Gy of radiotherapy in September and October 2023. However, follow-up X-rays revealed a pathological fracture at the anatomical neck of the humerus ( Fig. 1 ). Despite pain resolution following primary treatment, radiographic assessment consistently demonstrated absence of callus formation and no progression toward union over a six-month observation period, leaving the patient with a significant functional impairment, unable to move his shoulder.
The team conducted a staging workup, including positron emission tomography (PET)/CT and chest CT. The PET/CT scan revealed high 18 F-fluorodeoxyglucose (FDG) uptake in the humeral tumor (maximum standardized uptake volume (SUV max ), 30) ( Fig. 2 ). Chest CT showed a new 6.3-mm diameter solid nodule in the left lower lobe of the lung with mild uptake on PET/CT (SUV max 2.2) ( Fig. 3 ). These results indicated a partial response to chemo-radiotherapy rather than complete remission. Given its small size, low and non-specific metabolic activity, and the absence of other extra-nodal sites of disease, it was most consistent with an inflammatory or incidental finding rather than a metastatic deposit or synchronous primary malignancy. The team decided to pursue active radiologic surveillance rather than immediate biopsy. Serial chest CT examinations were performed at 3-month intervals over the 1-year follow-up period. The nodule demonstrated no increase in size or FDG avidity, lending further support to a benign etiology. No dedicated biopsy was performed, given the nodule's stable radiologic behavior.
Magnetic resonance imaging (MRI) of the humerus confirmed an extensively destructive bone lesion ~15 cm in length, invading surrounding tendons and muscles, but not the neurovascular bundle ( Fig. 4 ). Taken together, these findings suggested a case of primary bone lymphoma with a partial treatment response, which was complicated by a pathological fracture following radiotherapy. MRI and PET/CT findings were consistent with residual lymphomatous disease after therapy completion.
Histopathological examination of the initial biopsy revealed a diffuse pattern of cells with round nuclei, scant cytoplasm and frequent mitoses, suggestive of lymphoma. Due to the rarity of PLB, a differential diagnosis, including Ewing sarcoma and small cell osteosarcoma, was considered. The diagnosis was confirmed by immunohistochemical staining, which showed strong CD20 positivity, and positivity for BCL6 (>30%) and multiple myeloma oncogene 1 (MUM1) (>30%), and a high proliferation index with Ki67 (>90%). These markers confirmed DLBCL diagnosis, non-germinal center B-cell type ( Fig. 5 ).
The multidisciplinary tumor board of our hospital recommended surgery, given the non-healing fracture and persistent functional deficit post-treatment. Pre-operative planning was facilitated using a 3-dimensional (3D) printed model of the patient's proximal humerus, constructed from CT imaging data, to guide implant selection and simulate the surgical reconstruction (3D Technology in Medicine Center, College of Health Sciences, Vin University) ( Fig. 6A ). The patient underwent a 20 cm-wide resection of the proximal humerus ( Fig. 6B ), and a 6-cm segment of the resected humeral diaphysis was treated with liquid nitrogen to serve as a devitalized cortical autograft ( Fig. 6C ). The liquid nitrogen protocol followed established oncological bone recycling principles: The bone segment was immersed in liquid nitrogen at −196°C for 20 min, then allowed to thaw at room temperature for 15 min, followed by thawing in sterile normal saline for 15 min. This freeze-thaw cycle ensured complete devitalization of residual tumor cells while preserving the cortical bone's structural integrity ( 8 ).
Reconstruction was performed using a modular reverse shoulder megaprosthesis (Beijing Chunli Zhengda Medical Instrument Co., Ltd.) with a 10.5-cm intramedullary stem. The devitalized autograft was then secured to the prosthetic stem using polymethylmethacrylate cement and fixed to the remaining humeral diaphysis using a plate and screws to achieve rotational stability ( Fig. 6D ). Soft-tissue reconstruction was critical to optimize reverse shoulder construct function. As the rotator cuff tendons had been resected en bloc with the specimen, the remaining deltoid muscle was meticulously sutured to pre-designed holes of the humeral prosthetic component, and the residual musculature was re-approximated to the autograft using non-absorbable sutures. This soft-tissue envelope reconstruction was essential for reverse shoulder megaprosthesis function to provide dynamic stability and prevent dislocation ( 9 ).
Postoperatively, the patient followed a structured rehabilitation program beginning with passive range-of-motion exercises at 2 weeks and progressing to active-assisted exercises at 6 weeks. At the 1-year follow-up, the patient was assessed using the Musculoskeletal Tumor Society (MSTS) scoring system ( 10 ). The preoperative MSTS score was 8/30, reflecting severe functional impairment, and improved to 22/30 at the 1-year follow-up. The patient continues to be monitored every 3 months and remains stable with no signs of local recurrence or distant metastasis on imaging ( Fig. 6E ).
Discussion
This case is notable for two primary reasons: The diagnostic challenge presented by a rare tumor and, more significantly, the management of a severe post-treatment complication with a novel surgical technique. Primary lymphoma of bone is rare, predominantly affecting males, with a median diagnostic age in the 7th decade ( 11 ), but the patient of the present study was considerably younger. While local pain is a common presenting symptom, pathological fractures occur in a substantial number of cases (25–30%) and are prognostically significant ( 12 ).
Diagnosing PLB can be difficult, as its morphology overlaps with other round cell tumors. As demonstrated in the present case, small or decalcified biopsy samples can further complicate diagnosis. The present findings underscore immunohistochemistry's pivotal role in reaching a definitive diagnosis. The sample's strong positivity for B-cell markers CD20 and CD45 ( 13 ), along with the specific profile of BCL6, MUM1 and a high Ki-67 index, was crucial in confirming DLBCL and excluding mimics like Ewing sarcoma.
The primary PLB management is a combination of chemotherapy and radiotherapy. Surgery is typically reserved for obtaining a diagnosis or for managing complications like pathological fractures. The optimal surgical timing and method for these fractures are not well-established. Scoccianti et al ( 14 ) documented various approaches, including conservative management, fixation and resection, with the timing of surgery varying from pre- to post-chemotherapy.
In the present case, the decision to perform surgery after the completion of both chemotherapy and radiotherapy was based on the patient's specific clinical situation: A non-healing fracture causing significant functional loss, despite the patient being pain-free. This aligned with the principle of intervening to enhance function and quality of life. The present surgical technique addressed substantial bone loss and soft tissue involvement, consistent with recommendations to consider wide excision in such scenarios. Furthermore, complete resection was supported by evidence suggesting improved survival rates compared to incomplete resection ( 15 ). The uniqueness of the present surgical approach lies in the combination of a reverse shoulder arthroplasty with the use of a liquid nitrogen-treated autograft. This technique aimed to provide stability and improve shoulder function while preserving the patient's bone stock, representing an innovative evolution in our surgical practice for humeral cancers ( 16 ). Furthermore, Schmitz et al ( 15 ) reported that survival was significantly higher in patients who underwent complete resection compared to those who underwent incomplete resection. This supports our decision to proceed with wide excision followed by megaprosthesis replacement.
To contextualize the innovation of the proposed hybrid approach, it is useful to compare it directly to the principal alternatives: Structural allograft composite arthroplasty and megaprosthesis reconstruction alone. Osteoarticular or intercalary allografts offer biological reconstruction and the potential for tendon reattachment to host tissue. However, they have high complication rates, including infection, fracture and non-union, and carry the additional risk of disease transmission ( 17 ). Furthermore, allografts are not universally available, particularly in resource-limited healthcare settings such as Vietnam, where the bone banking infrastructure remains underdeveloped. Additionally, reconstruction with megaprosthesis alone, while durable and immediately stable, sacrifices all residual bone stock. In many cases, this option is not feasible when there is not enough bone left to attach the implant stem.
The hybrid technique described in this report addresses these limitations by combining the immediate mechanical stability of the modular reverse shoulder prosthesis with the biological advantages of the patient's own devitalized cortical bone. The recycled autograft serves as a bridging scaffold that facilitates soft-tissue attachment, augments the bone-prosthesis interface and preserves the patient's residual cortical stock-all without the immunological concerns or availability constraints of an allograft. This approach represents a pragmatic and reproducible innovation particularly suited to centers where commercial allografts are unavailable.
In conclusion, this case of primary diffuse large B-cell lymphoma of the bone highlights the critical importance of immunohistochemistry for accurate diagnosis when faced with histopathological mimics. Additionally, the non-healing pathological fracture of the present patient required a highly specialized intervention. This case underscores that PLB treatment goals should extend beyond oncological control to include limb function preservation and improved quality of life, necessitating a creative and individualized multidisciplinary approach.
Acknowledgements
Not applicable.
Availability of data and materials
The data generated in this study may be requested from the corresponding author.
Authors' contributions
DTT and VKN conceived the study and wrote original manuscript. MQD and THL summarized data, operated on the patient and confirmed the authenticity of the raw data. TQSN operated on the patient and contributed to writing the manuscript. VAN reviewed the results of diagnostic imaging. TTHaT and VCT collected, validated and interpreted the patient's chemotherapy and radiotherapy treatment data. TTHiT and TDT followed up and interpreted the patient's outcome. All of the authors have read and approved the final manuscript.
Ethics approval and consent to participate
This study's procedures adhered to the tenets of the Declaration of Helsinki. Case reports are approved by the Joint Consultation for Approval of Surgery of Vinmec Times City International Hospital, Vinmec Healthcare System, 458 Minh Khai, Vinh Tuy, Hanoi and are exempt from requiring ethical approval at the Vinmec Healthcare System.
Patient consent for publication
Written informed consent was obtained from the patient for the publication of this case report, including clinical information and accompanying images.
Competing interests
The authors declare that they have no competing interests.
Abbreviations
primary lymphoma of bone
diffuse large B-cell lymphoma
magnetic resonance imaging
computed tomography
References
1 Jiang M Bennani NN Feldman AL Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms Expert Rev Hematol 10 239 249 2017 10.1080/17474086.2017.1281122 28133975 PMC5514564
2 Shanbhag S Ambinder RF Hodgkin lymphoma: A review and update on recent progress CA Cancer J Clin 68 116 132 2018 29194581 10.3322/caac.21438 PMC5842098
3 Choi JY Hahn JS Suh CO Yang WI Primary lymphoma of bone-Survival and prognosis Korean J Intern Med 17 191 197 2002 10.3904/kjim.2002.17.3.191 12298430 PMC4531681
4 Yohannan B Rios A Primary diffuse large B-cell lymphoma of the bone J Hematol 12 75 81 2023 10.14740/jh1087 37187495 PMC10181325
5 Rezazadeh A Szabo A Khurana A Inwards DJ Lunning MA Bartlett NL Caimi PF Rodgers TD Barr PM Chowdhury SM Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: A multicenter, retrospective study Haematologica 109 1439 1444 2024 37855051 10.3324/haematol.2023.283210 PMC11063852
6 Kanavos T Birbas E Papoudou-Bai A Hatzimichael E Kitsouli A Karpathiou G Kanavaros P Primary bone lymphoma: A review of the literature with emphasis on histopathology and histogenesis Diseases 11 42 2023 10.3390/diseases11010042 36975591 PMC10047712
7 Edge SB Compton CC The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM Ann Surg Oncol 17 1471 1474 2010 10.1245/s10434-010-0985-4 20180029
8 Dang QM Nguyen Tran Quang SQ Duc TT Dung TT Tran Van C Le HT Tran HTT Van Nguyen K 128P. Innovative limb salvage: Liquid nitrogen approach in reconstruction after bone tumor resection ESMO Open (Suppl 2) 9 102517 2024 10.1016/j.esmoop.2024.102517
9 Cianni L Capece G Fiore L De Fazio A Martellini S Maccauro G Saccomanno MF Glenohumeral instability and clinical outcomes following proximal humerus resection and megaprosthesis implantation: A systematic review J Clin Med 14 7850 2025 10.3390/jcm14217850 41227244 PMC12609309
10 Rizzo A Paderno M Saccomanno MF Milano F Milano G The Musculoskeletal Tumor Society Scoring system is a valid subjective and objective tool to evaluate outcomes of surgical treatment of patients affected by upper and lower extremity tumors Musculoskelet Surg 108 201 214 2024 10.1007/s12306-024-00815-3 38485902 PMC11133199
11 Benkhadra R Auster M Nayfeh T Abbas AS Alsibai R Benkhadra K Datta P Kaur S Systematic review determining the characteristics of primary bone lymphoma J Clin Oncol 41 (Suppl 16) e19543 2023 10.1200/JCO.2023.41.16_suppl.e19543
12 Cai L Stauder MC Zhang YJ Poortmans P Li YX Constantinou N Thariat J Kadish SP Nguyen TD Kirova YM Early-stage primary bone lymphoma: A retrospective, multicenter Rare cancer network (RCN) study Int J Radiat Oncol Biol Phys 83 284 291 2012 10.1016/j.ijrobp.2011.06.1976 22079728
13 Chisholm KM Ohgami RS Tan B Hasserjian RP Weinberg OK Primary lymphoma of bone in the pediatric and young adult population Hum Pathol 60 1 10 2017 10.1016/j.humpath.2016.07.028 27554207
14 Scoccianti G Rigacci L Puccini B Campanacci DA Simontacchi G Bosi A Capanna R Primary lymphoma of bone: Outcome and role of surgery Int Orthop 37 2437 2442 2013 10.1007/s00264-013-2055-6 23974836 PMC3843197
15 Schmitz C Rekowski J Müller SP Farsijani N Hertenstein B Franzius C von Verschuer U La Rosée P Freesmeyer M Wilop S Impact of complete surgical resection on outcome in aggressive non-Hodgkin lymphoma treated with immunochemotherapy Cancer Med 9 8386 8396 2020 10.1002/cam4.3448 32926763 PMC7666729
16 Tran DT Tran TD Nguyen SB Nguyen SQT Dang QM Tran CV Combination of reverse shoulder prosthesis, elbow prosthesis, and polyetheretherketone: A modified total humeral replacement for osteosarcoma humerus treatment Case Rep Oncol 15 12 20 2022 10.1159/000519599 35221964 PMC8832199
17 Wisanuyotin T Paholpak P Sirichativapee W Kosuwon W Allograft versus autograft for reconstruction after resection of primary bone tumors: A comparative study of long-term clinical outcomes and risk factors for failure of reconstruction Sci Rep 12 14346 2022 10.1038/s41598-022-18772-x 35999284 PMC9399236